Sagona Capital, Inc. focuses on seed and early-stage medtech companies involved especially in medical devices industry, instrumentation, diagnostics, imaging, healthcare IT, robotics, artificial intelligence (deep/machine learning), real-time disease monitoring, patient treatment (remote consultation and follow-up) and efficiency of the patient’s care path.
Since this health crisis caused by COVID-19 Medtech plays a vital role saving lives, improving heath, contributing to sustainable healthcare and ensuring that professionals can work safely through innovative devices and diagnostics. Medtech companies are also drivers of economic growth and job creation across the United States and Europe.
Our Portfolio focuses on innovative businesses at seed and early stage with modern approaches to established leaders expanding into new markets. We aim to invest in companies that address unmet healthcare and economic needs in potential new markets created by technological advancements.
We seek device or technology which create a new treatment modality or represent a substantial improvement. The companies must have a business model that provides a sustainable advantage, the potential to serve a significant addressable global market with a robust intellectual property protection resulting in potential breakthrough therapies and must fit an area of strategic need for potential acquirers.
Sagona Capital, Inc. brings more than just investment capital. We act as a true value-added investor and support healthcare companies in achieving value-creating milestones. Through our USA-Europe bridge and our extended network, we work closely with the companies by providing operational, regulatory, commercial, administrative and clinical expertise driven by the support of key opinion leaders in the scientific communities.
Our mission is also supported by a dedicated team of advisors who have access to a broad network within academic, finance and industry providing insight and guidance to the portfolio companies. We take an active role in the development of our portfolio companies as a lead or a syndicate partner.